Jyong Biotech's Remarkable Achievement in Biotech Awards
Jyong Biotech Ltd. (Nasdaq: MENS), a pioneering biotechnology company committed to improving health through innovative plant-derived drugs, has recently made headlines by winning the prestigious Innovation Gold Award at the Taipei Biotech Awards. This recognition came due to their exceptional work on BOTRESO, a groundbreaking investigational drug aimed at treating benign prostatic hyperplasia (BPH) and lower urinary tract syndrome (LUTS). The award ceremony, likened to the Oscars of the biotech domain, was a significant event in the life sciences sector.
The Journey of BOTRESO
The product recognized in the Innovation Gold Award category, BOTRESO, has garnered multiple global invention patents, underlining its uniqueness and effectiveness. The drug has successfully completed four Phase III clinical trials across the United States and Taiwan, positioning it as a strong contender in the pharmaceutical market. Not only is BOTRESO the first oral botanical drug developed in Taiwan, but it also represents a significant step in securing U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) approval.
Impact of Recognition
Fu-Feng Kuo, the Chairwoman and CEO of Jyong Biotech, expressed immense pride and gratitude for their achievements. She stated that receiving the Innovation Gold Award underscores the years of dedicated research and innovation dedicated to developing BOTRESO. This accolade not only reflects the company’s commitment to advancing healthcare solutions but also its potential to transform patient care on a global scale.
Future Aspirations
With the recognition from the Taipei Biotech Awards, Jyong Biotech is motivated to enhance its global footprint. The company is focused on expanding its innovative portfolio and meeting the unmet healthcare needs of patients worldwide. They are steadfast in their mission to provide safe and effective therapies through continued research and development.
About Jyong Biotech Ltd.
Established in 2002, Jyong Biotech Ltd. has emerged as a leader in the biotechnology field, primarily dedicated to the development of plant-derived pharmaceutical products. The company’s operations encompass an extensive range of functionalities in drug development, from initial discovery to regulatory affairs and commercialization. Jyong Biotech has developed an impressive arsenal of botanical drug candidates, including BOTRESO, which targets critical healthcare challenges.
Commitment to Quality and Innovation
Jyong Biotech takes pride in its robust research and development capabilities, which are complemented by a proprietary platform facilitating the advancement of their treatments. The company’s ongoing research aims to create a diverse range of novel therapeutic drugs that cater to the growing health needs of the global population.
Contact Information
If you seek further information regarding Jyong Biotech Ltd. or its innovative products, please reach out to the company’s investor relations team:
For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang
Email: services@wealthfsllc.com
Phone: +1 628 283 9214
Frequently Asked Questions
What is the significance of the Innovation Gold Award?
The Innovation Gold Award recognizes exceptional achievements in the biotechnology field, celebrating advancements such as Jyong Biotech's BOTRESO.
What condition does BOTRESO treat?
BOTRESO is primarily developed for the treatment of benign prostatic hyperplasia (BPH) and lower urinary tract syndrome (LUTS).
How many clinical trials has BOTRESO completed?
BOTRESO has successfully completed four Phase III clinical trials in both the U.S. and Taiwan.
What are the future plans for Jyong Biotech?
Jyong Biotech plans to expand its global presence and further innovate in the field of plant-derived therapies.
How can I learn more about Jyong Biotech's products?
For detailed information on Jyong Biotech's products and innovations, please refer to their corporate website or contact investor relations.
